Efficacy of Median Nerve Hydrodissection by Hyalase Versus Midazolam in the Treatment of Carpal Tunnel Syndrome:

Efficacy of Median Nerve Hydrodissection by Hyalase Versus Midazolam in the Treatment of Carpal Tunnel Syndrome: A Randomized, Clinical Trial.

Status

UNKNOWN

Phases

Early Phase 1

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT05344495

Enrollment

100

Registered

2022-04-25

Start date

2022-01-10

Completion date

2022-08-01

Last updated

2022-06-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pain, Neuropathic

Brief summary

Comparing efficacy of hyalase and midazolam in median nerve entrapement neuropathy

Interventions

DRUGhyalase group

bupivacaine 15 mg 0.5% plus 2 mL normal saline containing 300 international units (IU) hyaluronidase.

DRUGmidazolam group

2 mg midazolam dissolved in 2 ml sterile saline plus 15 mg bupivacaine 0.5%

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender

ALL

Age

30 Years to 70 Years

Healthy volunteers

Inclusion criteria

* adult patients (30 - 70 years old) complaining of carpal tunnel syndrome of 3 month duration or more , diagnosed axonal neuropathy using electrodiagnosis , nerve conduction study refractory to medical treatment for 2 months .

Exclusion criteria

* Diabetic patients * Pregnant population . * Refusal to participate

Design outcomes

Primary

Measure	Time frame	Description
pain score	6 months	visual analogue score which represents 0 = no pain, 10= worst un-imaginable pain

Secondary

Measure	Time frame	Description
Boston questionnaire	6 months	symptom severity ... function severity
median nerve sonogrphy	6 months	cross sectional area
Nerve electrophysiology	6 months	sensory velocity and distal motor latency ... 1m/sec is the least and 10m/sec is the highest

Countries

Egypt

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026